ADA June 25-29

The ADA 70th scientific session is fast approaching and promises to be another exciting year. No doubt, there will be more discussion on FDA's risk assessment guidance for diabetes.

Dr. David Orloff, former Head of FDA's Metabolic and Endocrine division has been on the forefront of this discussion over the past year:

http://www.medpace.com/AboutUs/NewsAndEvents/OnDemand/OrloffPodcast.aspx

In addition to the regulatory discussions on diabetes drug development, look for the promising drug/device combo development including pumps, CGM, SMBG, and in-hospital monitoring devices with DPP-4 inhibitors, GLP-1 therapy, insulin, non-insulin, non-incretin therapy, and novel drugs.

Have a good ADA meeting - see you there. Medpace is located at booth 1202!